Chances of FDA approval for Spectrum Pharma's lung cancer candidate poziotinib and Oncopeptides' Pepaxto for multiple myeloma have taken a dive, after the regulator's expert advisors voted
The European Commission has approved Oncopeptides' Pepaxti in combination with dexamethasone for multiple myeloma patients with so-called triple class refractory disease – in other words th
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
